Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations
Journal of Clinical Investigation · 01.04.2025 · 135 (7)
DOI: 10.1172/jci186423 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.04.2025. Verfasst von Bernd Schnabl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology, UCSD, San Diego, California, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Dysbiosis, Fatty Liver. Die Arbeit wurde bisher 128-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of liver disease worldwide, and our understanding of its pathogenesis continues to evolve. MASLD progresses from steatosis to steatohepatitis, fibrosis, and cirrhosis, and this Review explores how the gut microbiome and their metabolites contribute to MASLD pathogenesis. We explore the complexity and importance of the intestinal barrier function and how disruptions of the intestinal barrier and dysbiosis work in concert to promote the onset and progression of MASLD. The Review focuses on specific bacterial, viral, and fungal communities that impact the trajectory of MASLD and how specific metabolites (including ethanol, bile acids, short chain fatty acids, and other metabolites) contribute to disease pathogenesis. Finally, we underscore how knowledge of the interaction between gut microbes and the intestinal barrier may be leveraged for MASLD microbial-based therapeutics. Here, we include a discussion of the therapeutic potential of prebiotics, probiotics, postbiotics, and microbial-derived metabolites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Gastroenterology, UCSD, San Diego, California, USA.
- Department of Medicine, VA San Diego Healthcare System, San Diego, California, USA.
- Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, Washington, USA.
Förderung
- NIDDK NIH HHS
- NIAAA NIH HHS
Zitieren
APA
Schnabl, B., Damman, C. J., & Carr, R. M. (2025). Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. Journal of Clinical Investigation, 135(7). https://doi.org/10.1172/jci186423
Vancouver
Schnabl B, Damman CJ, Carr RM. Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. Journal of Clinical Investigation. 2025;135(7). doi:10.1172/jci186423
BibTeX
@article{Schnabl2025,
author = {Schnabl, Bernd and Damman, Christopher J and Carr, Rotonya M},
title = {Metabolic dysfunction–associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {7},
doi = {10.1172/jci186423}
}
EUVIMED